Alberta Health Services, Calgary, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
ICES, Toronto, Canada.
Drug Alcohol Depend. 2024 Nov 1;264:112451. doi: 10.1016/j.drugalcdep.2024.112451. Epub 2024 Sep 24.
Injectable extended-release buprenorphine (BUP-ER) (Sublocade®) is a newer form of opioid agonist therapy (OAT) administered monthly. It was listed on formularies across Canada in February 2020, expanding the options for OAT across the country. This study describes rates of injectable BUP-ER uptake in five provinces to compare access to this novel medication across Canada.
We conducted a retrospective time-series analysis among individuals who received injectable BUP-ER in British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario from February 1, 2020, to March 31, 2022. The primary outcome was the population-adjusted rate of injectable BUP-ER in each province, with secondary analyses exploring rates by urban/rural location, and the number of prescribers of injectable BUP-ER per 100,000 population.
In total, 6528 individuals were treated with injectable BUP-ER, with the majority in British Columbia (29.0 %) and Ontario (47.0 %). By March 2022, the rate of BUP-ER use was highest in British Columbia (16.6 per 100,000), and lowest in Ontario (9.1 per 100,000). The rate of BUP-ER use was higher in rural areas (15.5 per 100,000) compared to urban centres (10.6 per 100,000), and British Columbia had the highest rate of prescribers per 100,000 population (5.9) compared to Ontario (2.2), Alberta (2.3), Saskatchewan (3.4) and Manitoba (3.5) by the end of Q1-2022.
Uptake of BUP-ER varied geographically since being approved by Health Canada. More rapid uptake in rural areas is reassuring and suggests that this form of OAT may be supporting treatment access to those with barriers to more traditional treatment formulations.
可注射的延长释放丁丙诺啡（BUP-ER）（Sublocade®）是一种新形式的阿片类激动剂治疗（OAT）药物，每月注射一次。2020 年 2 月，该药物在加拿大各地的处方目录中列出，这在全国范围内扩大了 OAT 的选择。本研究描述了在五个省份使用可注射 BUP-ER 的比例，以比较加拿大各地获得这种新型药物的情况。
我们对 2020 年 2 月 1 日至 2022 年 3 月 31 日期间在不列颠哥伦比亚省、艾伯塔省、萨斯喀彻温省、马尼托巴省和安大略省接受可注射 BUP-ER 治疗的个体进行了回顾性时间序列分析。主要结局是每个省的人群调整后的可注射 BUP-ER 比例，次要分析探讨了城乡位置和每 10 万人中可注射 BUP-ER 处方数的比例。
共有 6528 人接受了可注射 BUP-ER 治疗，其中大多数在不列颠哥伦比亚省（29.0%）和安大略省（47.0%）。到 2022 年 3 月，BUP-ER 的使用率最高的是不列颠哥伦比亚省（16.6/10 万人），最低的是安大略省（9.1/10 万人）。农村地区（15.5/10 万人）的 BUP-ER 使用率高于城市中心（10.6/10 万人），到 2022 年第一季度末，不列颠哥伦比亚省每 10 万人中开具 BUP-ER 处方的医生数量最高（5.9），而安大略省（2.2）、艾伯塔省（2.3）、萨斯喀彻温省（3.4）和马尼托巴省（3.5）。
自从 BUP-ER 获得加拿大卫生部批准以来，它的使用在地理上有所不同。在农村地区更快的吸收令人欣慰，这表明这种形式的 OAT 可能支持那些接受传统治疗方案存在障碍的人的治疗机会。
